← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Visikol, Inc.
Hampton, NJ
$3,558,044
Total funding
6
Grants
Funding over time
peak $1M · FY2016–22$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,134,045 · 3
NSF$1,423,999 · 3
By mechanism
R44$1,629,519 · 1
—$1,423,999 · 3
R43$504,526 · 2
Investigators at Visikol, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
SBIR Phase II: Digitization of Skeletal Evaluations for Developmental and Reproductive Toxicology (DART) Studies.$973,999
· FY2019 · TIP
Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma$844,227
R44 · FY2021 · CA
Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma$785,292
R44 · FY2022 · CA
SBIR Phase I: Digitization of Skeletal Evaluations for Developmental and Reproductive Toxicology (DART) Studies.$225,000
· FY2018 · TIP
SBIR Phase I: Improved Skeletal Visualization Technology for Developmental and Reproductive Toxicology (DART) Studies$225,000
· FY2016 · TIP
Development of a High-Throughput Three-Dimensional H&E Platform for the Characterization of Breast Cancer Biopsies$225,000
R43 · FY2018 · CA
Improved Characterization of 3D In Vitro Cell Culture Assays for the Drug Discovery Process$224,526
R43 · FY2018 · GM
Development of a High-Throughput Three-Dimensional H&E Platform for the Characterization of Breast Cancer Biopsies$55,000
R43 · FY2019 · CA